Antibiotic consumption in laboratory confirmed vs. non-confirmed bloodstream infections among very low birth weight neonates in Poland

A. Różańska1*, J. Wójkowska‑Mach1, P. Adamski2, M. Borszewska‑Kornacka3, E. Gulczyńska4, M. Nowiczewski4, E. Helwich5, A. Kordek6, D. Pawlik7 and M. Bulanda1

Abstract

Background: Newborns are a population in which antibiotic consumption is extremely high. Targeted antibiotic therapy should help to reduce antibiotics consumption. The aim of this study was an assessment of antibiotic usage in bloodstream infections treatment in the Polish Neonatology Surveillance Network (PNSN) and determining the possibility of applying this kind of data in infection control, especially for the evaluation of standard methods of microbiological diagnostics.

Methods: Data were collected between 01.01.2009 and 31.12.2013 in five teaching NICUs from the PNSN. The duration of treatment in days (DOT) and the defined daily doses (DDD) were used for the assessment of antibiotics consumption.

Results: The median DOT for a single case of BSI amounted to 8.0 days; whereas the median consumption expressed in DDD was 0.130. In the case of laboratory confirmed BSI, median DOT was 8 days, and consumption—0.120 DDD. Median length of therapy was shorter for unconfirmed cases: 7 days, while the consumption of antibiotics was higher—0.140 DDD (p < 0.0001). High consumption of glycopeptides expressed in DOTs was observed in studied population, taking into account etiology of infection.

Conclusions: Even application of classical methods of microbiological diagnostics significantly reduces the consumption of antibiotics expressed by DDD. However, the high consumption of glycopeptides indicates the necessity of applying rapid diagnostic assays. Nevertheless, the assessment of antibiotic consumption in neonatal units represents a methodological challenge and requires the use of different measurement tools.

Keywords: Antimicrobial consumption, Infection surveillance, Bloodstream infections, Neonatal infections
countries and in the United States, but there are no such reports from Poland or Central Europe.

Assessment of antibiotic usage in neonatal intensive care units encounters significant difficulties connected with the lack of standardized methods for this specific patient population. Defined daily dose (DDD), an international standard measure used for drug consumption assessment, is a technical unit of measurement which reflects the average maintenance dose per day for a drug used for its main indication in adults [12]. For this reason, this parameter has certain limitations for the analysis in the child population. However, defined daily dose was used in some studies, especially for comparative purposes in homogenous patient population [13]. Other parameters used for antibiotic usage assessment are as follows: LOT—the number of days during which at least one dose of any antibiotic was received, DOT—the aggregate sum of LOT or PDD—prescribed daily dose or proportion of patients with antibiotic treatment in a specific period [14–16].

Antibiotics consumption assessment can have numerous implications. In the area of infection control it can serve as a relatively simple indicator for assessing the effectiveness of methods of microbiological diagnostics. Microbiological diagnostics of blood stream infections in hospital practice still remains a challenge.

The aims of this study were:

- an assessment of antibiotic usage in bloodstream infection (BSI) treatment, taking into account etiology, in the Polish Neonatal Surveillance Network wards using two kinds of parameters, that is DDD and DOT,
- determining the possibility of applying this kind of data in infection control, especially for the evaluation of standard methods of microbiological diagnostics.

Methods

Data were collected prospectively between 01.01.2009 and 31.12.2013 in five teaching neonatal intensive care units (NICU) that took part in the Polish Neonatology Surveillance Network (PNSN). The PNSN is a prospective national surveillance system for the most relevant infections in the group of very low birth weight (birth weight <1500 g, VLBW) infants in Poland. The PNSN recorded severe infections, including BSI, observed during hospitalization: from admission to discharge, transfer or death. Participation in PNSN was voluntary and confidential for wards. Detailed description of data collection system, study wards, epidemiology of early- and late-onset BSI and its microbiology have been already published elsewhere [1, 7]. The study was approved by the Bioethics Committee of Jagiellonian University Medical College—no. KBET/221/B/2011. All data entered into the electronic database and analyzed retrospectively during the preparation of this article were previously de-identified. BSI (both: early- and late-onset) were defined according to Gastmeier et al. [17] with modifications. BSI was detected when at least two of the following signs were observed:

- Temperature >38 or <36.5 °C or temperature instability, tachycardia or bradycardia, apnea, prolonged capillary refill, metabolic acidosis, hyperglycemia, the other sign of bloodstream infections, such as: lethargy; and one of the following criteria: C-reactive protein (CRP) >2.0 mg/dL, immature/total neutrophil ratio (I/T ratio) >0.2, leukocytes <5000/µL, platelets <10,000/µL.

Early-onset BSI was defined as septicemia diagnosed <3 days after delivery.

Laboratory confirmed BSI (LC-BSI) were those cases in which positive results of the microbiological testing were obtained, that means etiological factor was isolated. All blood specimens of at least 1 mL (taken prior to implementing antibiotic treatment) were injected into an aerobic blood culture bottle. Isolates were identified by the automated identification system (VITEK 2, bioMérieux, Poland). In the studied wards, molecular methods for identification of etiological factors were not used. BSI cases in which samples for microbiological testing were not collected or etiological factor was not isolated were classified as not confirmed ones.

Antibiotic usage for BSI treatment (until cure) was assessed for 767 cases. The analysis of antibiotic use included only the cases in which treatment was successful—13 records concerning infants who had died within 7 days of starting the therapy were excluded from the study (all of them were laboratory confirmed).

Two kinds of indicators were used for the description of antibiotic usage:

1. DOT, expressed in days—the aggregate (for every separate type of antibiotics) sum of number of days during which at least one dose of any antibiotic was received, and
2. DDD, expressed in grams—the defined daily dose, according to the ATC/DDD system of the World Health Organization (Anatomical Therapeutic Chemical, group “J01”) [12].

Both measures were taken into account in reference to one case of infection. Data on the medicine type, dose, and the length of therapy were derived from individual records in the chart of each individual patient.
Antibiotic consumption were calculated for all antimicrobials used in therapy, and for the following classes: beta-lactams (ampicillin, cloxacillin, piperacillin, cefotaxime, ceftriaxone, ceftazidime, meropenem, imipenem), aminoglycosides (amikacin, netilmicin, gentamicin), glycopeptides (vancomycin), antymycotics (fluconazole, amphotericin B) and others (ciprofloxacin, clindamycin, erythromycin, clarithromycin, sulfamethoxazole with trimethoprim). Etiological factors were assigned to the following groups: Gram-negative (Enterobacteriaceae and other rods), Gram-positive (staphylococci, streptococci), candida. While conducting treatment with the application of drugs from several groups, used in parallel or consecutively, all of them were included into analysis. When, during treatment, positive microbiological cultures were obtained from different samples, or samples taken at different times (within 5 days), growth of microorganisms belonging to various groups (e.g. Escherichia coli and Candida albicans) was defined as cases of changing etiology (group “changing”).

Due to DDD and DOT distribution significantly different from the normality, the statistical analysis based on the Kruskal–Wallis test. If the significance had been obtained, analysis was supplemented by the post hoc Steel–Dwass test, with critical value p = 0.05. All analysis were provided with SAS JMP package.

Results
In the study period, records of 2003 VLBW newborns and 780 BSI cases (regardless of the date of recognition of first BSI symptoms) were filled with all data. Laboratory confirmed BSI (LC-BSI) constituted 84.9% (662) of all recognized cases of BSI.

In the analyzed population of VLBW neonates with BSI, in whom the etiological agent was isolated, combination therapy was used in 67% of cases, while in the group without microbiological confirmation, in 74% of cases.

The total duration of antibiotic therapy for 767 cases of BSI, which are incorporated into the present analysis, amounted to 14,056 DOTs or 381.6 DDDs. The median length of antibiotic therapy for a single case of BSI, regardless of microbiological confirmation or its lack, amounted to 8.0 days; whereas the median consumption expressed in DDD was 0.130. In the case of LC-BSI, median DOT was also 8.0 days, and consumption—0.120 DDD. Median length of therapy was shorter for unconfirmed cases: 7.0 days, while the consumption of antibiotics was higher—0.140 DDD (p < 0.0001) (Table 1).

Antibiotic consumption expressed by the DDD index was higher in the case of BSI caused by Gram-positive cocci than Gram-negative bacilli (0.140 vs. 0.136 DDD, Table 2), and the differences concerned 2× higher consumption of aminoglycosides (0.109 vs. 0.056 DDD, Table 2, p = 0.0092, Table 3).

Highest DOT values for beta-lactams concerned fungal infections and for the “changing” group, similarly to the consumption of antibiotics expressed by DDD.

Median length of therapy for BSI infections caused by Gram-positive cocci was longer than the ones caused by Gram-negative bacilli (9.0 vs. 7.5 DOT, Table 2), and the differences were mainly associated with the employment of glycopeptides (8.0 vs. 10.0 DOT, Table 2, p = 0.0004, Table 3).

Detailed data on antibiotic consumption expressed by DOT and DDD (values of medians per one infection case), taking into account groups of antibiotics, are presented in Table 2.

The results of statistical analysis regarding the consumption of the individual groups of antibiotics depending on the etiology of infection are shown in Table 3.

Depending on the applied indicator assessing the consumption of antibiotics in the treatment of BSI: DOT or DDD, the percentage share for individual groups of antibiotics varied.

| Table 1 Values (median) of DOT and DDD in bloodstream infections treatment in microbiologically confirmed (LC) vs. unconfirmed cases (Not-LC) |
| Antimicrobial group | Microbiologically confirmed N = 649 | Microbiologically unconfirmed N = 118 | p value | Microbiologically confirmed N = 649 | Microbiologically unconfirmed N = 118 | p value |
|----------------------|---------------------------------|---------------------------------|---------|---------------------------------|---------------------------------|---------|
| DOT (days)           | DOT (days)                      | DOT (days)                      |         | DOT (days)                      | DOT (days)                      |         |
| Aminoglycosides      | 7.0 (5.0; 9.3)                  | 7.0 (6.0; 7.0)                  | 0.5265  | 0.101 (0.050; 0.171)             | 0.095 (0.045; 0.179)             | <0.0001 |
| Antimycotic          | 12.5 (9.0; 16.0)                | 10.0 (7.8; 14.3)                | 0.210   | 0.210 (0.132; 0.040)             | 0.198 (0.073; 0.463)             |         |
| Beta-lactams         | 8.0 (5.0; 11.0)                 | 7.0 (6.8; 8.8)                  | 0.254   | 0.254 (0.136; 0.438)             | 0.300 (0.210; 0.420)             |         |
| Glycopeptides        | 10.0 (8.0; 11.0)                | 9.0 (7.0; 11.0)                 | 0.120   | 0.120 (0.080; 0.168)             | 0.120 (0.083; 0.146)             |         |
| Other                | 9.0 (6.0; 14.8)                 | 8.0 (5.0; 15.5)                 | 0.210   | 0.210 (0.105; 0.530)             | 0.098 (0.060; 0.410)             |         |
| Total                | 8.0 (5.0; 16.0)                 | 7.0 (5.0; 15.5)                 | 0.120   | 0.120 (0.050; 0.530)             | 0.143 (0.045; 0.463)             |         |

DOT days of therapy (per one infection case), DDD defined daily dose (per one infection case), IQR interquartile range, N number of BSI cases
In treatment of BSI as a whole, according to the DOT index, glycopeptides were used the longest: 42.1%, and, after taking into account the etiology of infection, it was the predominant group also in infections caused by Gram-positive cocci: 51%, in the event of changes in the etiological agent: 40.6%. In treatment of microbiologically unconfirmed BSI, glycopeptides were used in 33.8% DOT (Fig. 1).

The largest share in total consumption of antibiotics in all analyzed cases of BSI expressed by DDD was represented by beta-lactams: 32.6%, especially with microbiologically unconfirmed BSI: 53.2% (Fig. 2).

In the event when antibiotic consumption was evaluated by DDD, antifungal medication constituted almost one-fourth of the applied drugs, and when the unit of measurement was DOT—13.3% (Figs. 1, 2).

### Discussion

BSI represent a critical complication associated with hospitalization of very low birth weight (VLBW) infants, contributing to longer stay, and different long-term adverse outcomes. This phenomenon is well-understood and described [3, 7, 18–21], contrary to the subject under discussion, in which, unfortunately, data concerning antibiotic consumption are sparse and incomplete.

The proportion of microbiologically confirmed cases of BSI observed in the present study indicates similarity, but not identicalness, with other national programs. In the analysis of differences, attention should be paid to the applied definition of infections and different significance of microbiological findings for various types of surveillance. In American NHSN, in which to confirm LC-BSI, it was necessary to obtain at least 2 identical blood cultures, clinical sepsis was observed in 6.7–12.7% of infections [22], i.e. twice less frequently than in this study—significantly less restrictive in evaluating microbiological results. It unfortunately, indicates too rare application of the capabilities of contemporary microbiology in everyday clinical practice of the studied NICUs. This is confirmed by the results of a Cypriot study, in which LC-BSI constituted 96% of all BSIs [23]. Another matter is the debated problem of legitimacy of repeated blood drawing for cultures from VLBW newborns. Currently, it is more and more frequently assumed that, in this patient population, it is more justifiable to draw a single full-volume sample than to take two or more—even in the event of a result revealing typical skin contaminants, i.e. coagulase-negative staphylococci [24]. This is confirmed by the definitions adopted in the Netherlands [25], in NICHD Vermont Oxford Network [3] and the ones employed in the German national program called Neo-KISS [17].

The obtained data show that the use of diagnostics, even based on the standard, basic level, meaning culture, is a proceeding effectively affecting the consumption of antibiotics, and therefore, the costs of therapy, i.e. they reduce the consumption of antibiotics expressed by DDD.

The indicator most commonly used to assess the consumption of drugs, including antibiotics, is defined daily dose. This recognized international standard applicable in measuring the consumption of antibiotics is based on the average dose for the treatment of adults. For this reason, it is an indicator which, in relation to children, should be used with caution and one should take into account its limitations [26, 27].

### Table 2 Values (median) of DOT and DDD in bloodstream infections treatment according to etiological factors

| Etiology       | DOT (days) | DDD (IQR) |
|----------------|------------|-----------|
| Gram+ N = 452  |            |           |
| Aminoglycosides| 7.0 (5.0; 9.0) | 0.109 (0.560; 0.180) |
| Antimycotics   | 12.0 (9.3; 16.0) | 0.195 (0.131; 0.341) |
| Beta-lactams   | 7.0 (5.0; 10.0) | 0.252 (0.180; 0.420) |
| Glycopeptides  | 10.0 (8.0; 11.0) | 0.128 (0.088; 0.168) |
| Other          | 9.0 (5.0; 15.0) | 0.211 (0.096; 0.452) |
| Total          | 9.0 (5.0; 15.0) | 0.140 (0.056; 0.453) |
| Gram− N = 103  |            |           |
| Aminoglycosides| 6.0 (4.3; 8.0) | 0.056 (0.036; 0.137) |
| Antimycotics   | 12.0 (8.2; 17.0) | 0.228 (0.131; 0.360) |
| Beta-lactams   | 8.0 (4.0; 11.0) | 0.244 (0.096; 0.448) |
| Glycopeptides  | 8.0 (4.0; 9.0) | 0.098 (0.039; 0.149) |
| Other          | 8.5 (5.3; 10.8) | 0.229 (0.099; 0.608) |
| Total          | 7.5 (4.0; 17.0) | 0.136 (0.036; 0.447) |
| Changing N = 76|            |           |
| Aminoglycosides| 7.0 (5.0; 10.0) | 0.105 (0.061; 0.180) |
| Antimycotics   | 12.0 (10.0; 16.0) | 0.250 (0.158; 0.733) |
| Beta-lactams   | 7.0 (6.5; 11.0) | 0.281 (0.169; 0.495) |
| Glycopeptides  | 10.0 (7.0; 11.0) | 0.085 (0.056; 0.167) |
| Other          | 9.0 (6.0; 14.5) | 0.187 (0.120; 2.580) |
| Total          | 9.0 (5.0; 16.0) | 0.149 (0.056; 2.580) |
| Candida N = 18 |            |           |
| Aminoglycosides| 8.5 (4.8; 12.8) | 0.140 (0.070; 0.210) |
| Antimycotics   | 10.5 (9.0; 15.8) | 0.225 (0.092; 0.353) |
| Beta-lactams   | 12.0 (9.0; 19.5) | 0.250 (0.225; 0.715) |
| Glycopeptides  | 10.0 (7.3; 10.8) | 0.087 (0.063; 0.161) |
| Other          | 13.5 (10.0, 17.0) | 3.276 (0.153; 6.400) |
| Total          | 10.0 (4.8; 19.5) | 0.164 (0.063; 6.400) |

Changing—when, during treatment, positive microbiological cultures were obtained from different samples, or samples taken at different times (within 5 days), growth of microorganisms belonging to various groups (e.g. *Escherichia coli* and *Candida albicans*) was defined as cases of changing etiology (group “changing”).

DOT days of therapy (per one case), DDD defined daily dose (per one case), IQR interquartile range, N number of cases
Table 3  Statistical significance of antibiotic consumption expressed in DOT and DDD in bloodstream infections treatment according to etiological factor

|                | Candida | Gram– | Gram+ | Changing |
|----------------|---------|-------|-------|----------|
| DOT aminoglycosides (H = 6.5939, df = 4; p = 0.590) |         |       |       |          |
| Not LC         | 0.7346  | 0.4524| 0.9929| 0.2733   |
| Candida        | na      | 0.6917| 0.9235| 0.9962   |
| Gram–          | na      | na    | 0.4338| 0.2780   |
| Gram+          | na      | na    | 0.8323|          |
| Total DDD aminoglycosides (H = 31.7944, df = 4; p < 0.0137) |         |       |       |          |
| Not LC         | 0.7980  | 0.3370| 0.5284| 0.9576   |
| Candida        | na      | 0.3438| 0.9582| 0.9577   |
| Gram–          | na      | na    | 0.9962| 0.3480   |
| Gram+          | na      | na    | 1.0000|          |
| DOT antifungals (H = 2.5563, df = 4; p = 0.6346) |         |       |       |          |
| Not LC         | 0.9978  | 0.9978| 0.8403| 0.7241   |
| Candida        | na      | 0.9995| 0.9155| 0.8539   |
| Gram–          | na      | na    | 0.9885| 0.8474   |
| Gram+          | na      | na    | 0.9753|          |
| Total DDD antifungals (H = 16.5505, df = 4; p = 0.4042) |         |       |       |          |
| Not LC         | 0.1485  | 0.7166| 0.9926| 0.7086   |
| Candida        | na      | 0.3429| 0.4524| 0.9454   |
| Gram–          | na      | na    | 0.2909| 0.9236   |
| Gram+          | na      | na    | 0.1509|          |
| DOT beta-lactams (H = 15.0687, df = 4; p = 0.0046) |         |       |       |          |
| Not LC         | 0.0286  | 0.8176| 0.7340| 0.0039   |
| Candida        | na      | 0.2451| 0.1935| 0.3721   |
| Gram–          | na      | na    | 0.9978| 0.2494   |
| Gram+          | na      | na    | 0.1390|          |
| Total DDD beta-lactams (H = 11.2708, df = 4; p = 0.1930) |         |       |       |          |
| Not LC         | 0.6238  | 0.3438| 0.2861| 0.3044   |
| Candida        | na      | 0.9999| 0.9852| 1.0000   |
| Gram–          | na      | na    | 0.6380| 1.0000   |
| Gram+          | na      | na    | 0.7880|          |
| DOT glycopeptides (H = 19.0396, df = 4; p = 0.0008) |         |       |       |          |
| Not LC         | 0.9986  | 0.0481| 0.4925| 0.9997   |
| Candida        | na      | 0.4196| 0.9989| 0.9992   |
| Gram–          | na      | na    | 0.0004| 0.1049   |
| Gram+          | na      | na    | 0.6125|          |
| Total DDD glycopeptides (H = 0.4767, df = 4; p = 0.0010) |         |       |       |          |
| Not LC         | 0.8227  | 0.5865| 0.4612| 0.5951   |
| Candida        | na      | 1.0000| 0.4731| 0.9998   |
| Gram–          | na      | na    | 0.0498| 0.9802   |
| Gram+          | na      | na    | 0.0157|          |
| DOT other (H = 2.2959, df = 4; p = 0.6815) |         |       |       |          |
| Not LC         | 0.6828  | 0.9978| 0.9220| 0.9922   |
| Candida        | na      | 0.7617| 0.8871| 0.9772   |
| Gram–          | na      | na    | 0.9735| 0.9984   |
| Gram+          | na      | na    | 0.9999|          |
| Total DDD other (H = 3.8955, df = 4; p = 0.3787) |         |       |       |          |
| Not LC         | 0.9707  | 0.9538| 0.8169| 0.9981   |
| Candida        | na      | 0.9986| 0.4667| 0.5815   |
| Gram–          | na      | na    | 0.8990| 0.9884   |
| Gram+          | na      | na    | 0.9910|          |

p values for each pair of etiological factor groups are given in the table cells.

Changing—when, during treatment, positive microbiological cultures were obtained from different samples, or samples taken at different times (within 5 days), growth of microorganisms belonging to various groups (e.g. Escherichia coli and Candida albicans) was defined as cases of changing etiology (group “changing”).

DOT days of therapy, DDD defined daily dose, IQR interquartile range, na not applicable, Not LC not laboratory confirmed.
However, both measures: DDD and the length of therapy were used by different authors with the application of various denominators—the number of admissions, number of person days or with respect to the treatment of a single patient [13, 15].

To evaluate the consumption of antibiotics in pediatric wards, particularly neonatal units, Gerber et al. employed DOT [15]. Depending on the type of neonatal unit, they found the length of treatment to be in the range from 5.7 in medical NICUs to 34.3 DOT in surgical NICUs. Median DOT in this study was about forty percent higher than in the medical NICUs in the study by Gerber; however, due to distinct populations and different degrees of detail, it is difficult to explicitly compare these values. Studies concerning antibiotic consumption in the neonatal population are not numerous, but what is more important: the published papers present a differentiated approach to the subject and are carried out with the use of diverse methodology and for various needs [5, 11, 13, 26, 28].

However, the main objective of this study was the analysis of the evaluation of antibiotic consumption in the treatment of one form of infection in a narrow and specific patient population, giving special consideration to the possibility of its use in the evaluation of the effectiveness and accuracy of microbiological diagnostics as an element of surveillance of infections in NICU.

And so, in NICUs covered by the study, significantly lower consumption of antibiotics expressed by DDD was observed in the case of LC-BSI treatment, compared to
those in which the etiological agent was not isolated. On this basis, it can be concluded that the microbiological diagnosis of BSI in newborns treated in NICU was conducted properly and the results of microbiological tests were used in targeted therapy, what made it possible to obtain a reduction in the consumption of antimicrobial drugs and, consequently, the cost of treatment. In Polish NICUs, costs of medication account for nearly one-fifth of the total cost of treatment, the amount of which is inversely proportional to a child’s birth weight and directly proportional to the length of hospitalization [20].

A different situation was observed in the population of the PNSN neonates, who developed necrotising enterocolitis, wherein the length of therapy and consumption rates were not affected by the isolation of the potential etiological agent [29]. But with NEC, difficulties present themselves as regards obtaining material for microbiological examination, which would enable the isolation of the etiological agent. The quoted results concerning antibiotic consumption in NEC cases and the ones demonstrated in the present study regarding BSI illustrate the possibilities of how analyses in this respect could be utilized in infection control and, in particular, in evaluation of adequacy and effectiveness of microbiological diagnostics.

On the other hand, no significant differences in DOT values in cases of LC-BSI and microbiologically unconfirmed BSI were observed. This is contradictory to the current approach to modern antimicrobial stewardship: in newborn population, with suspected BSI, it is recommended to terminate antibiotic treatment after 48 h since the identification of symptoms, if the infection was not confirmed microbiologically. Even traditional diagnostics based on the culture method ensures obtaining a positive result (information on microbial etiology of infection) within 48 h [30, 31].

For antimicrobial stewardship to efficiently and effectively influence the reduction of antibiotic consumption, but not to decrease patient safety, in neonatal units, a principle of daily detailed review of the situation of neonates treated with antibiotics should be introduced, so as to minimize the intake of antibiotics in children, whose blood cultures and other clinical specimens tested negative and symptoms of infection are no longer observed or infectious origin of the disease was excluded. The lack of significant differences in DOT values of laboratory confirmed vs. not-confirmed BSI cases would point to the fact that these recommendations are not applied in the PNSN wards.

It should also be noted that rapid diagnostic molecular methods (which enable rapid assessment of the need to implement or discontinue therapy with vancomycin) could be implemented to decrease glycopeptides consumption, because glycopeptides are not easy to use in neonates [32, 33]. For it has been observed that the use of glycopeptides in the case of BSI caused by Enterobacteriaceae was lower by only approx. 20% in comparison with BSI caused by Gram-positive cocci. Generally, in our study, in treatment of BSI as a whole glycopeptides were used the longest. Similar situation was reported in study of Sameer et al. [34].

As for aminoglycosides, only the use of the DDD indicator permitted the demonstration of their significantly increased consumption in BSI caused by Gram-positive cocci (109 DDD), in comparison with BSI that were caused by Gram-negative bacilli (56.1 DDD).

Also noteworthy is the fact that there is a large share of antifungal drugs in the treatment of the analyzed cases of BSI, 25% of the entire consumption expressed by DDD (13.3% DOT), with simultaneous, lower than anticipated, participation of yeast-like fungi isolated in microbiological testing [35, 36]. This coincides with the trends observed in other studies. According to Fridkin, the application of fluconazole in infection prophylaxis contributed to this fact, which is also confirmed by other authors [6]. Thus, the high level of antymycotic medication consumption in PNSN wards fulfilled the task of reducing the incidence of fungal infections.

Antibiotic consumption assessment using at least two different measures, as presented in our study, can be a useful tool in antibiotic stewardship [27]. In presenting case, the results of the analysis indicate the need of implementing more sensitive and faster methods of microbiological diagnostics (PCR and/or MALDI-TOF) as a first step of reducing antibiotics consumption due to faster identification of etiological factor of infection. PCR increases the sensitivity of diagnostics test and shortens the time of identification of microorganisms without culture. MALDI-TOF improves the specificity and shortens the time of identification after receiving microorganism grow in culture method [37, 38]. These diagnostics techniques are still very rarely used in Polish hospital. They are considered as expensive procedures by hospitals’ management, because complex cost-effectiveness analysis in the field of infection control, taking into account at least the cost of prolonged hospital stay, are not performed. In the study patient population occurrence of BSI significantly increases length of stay in NICU, by approximately 20 days [21].

**Conclusions**

Analysis of antibiotic consumption is an essential component of infection control, especially for NICU patients—for effective planning and reliable evaluation of interrelationships between individual elements of control programs.
Application of classical methods of microbiological diagnostics based on blood cultures significantly reduces the consumption of antibiotics expressed by DDD.

High consumption of glycopeptides marked by DOT indicates the necessity of applying rapid diagnostic assays.

Nevertheless, the assessment of antibiotic consumption in neonatal units represents a methodological challenge and requires the use of different measurement tools.

Abbreviations
BSI: bloodstream infection; DOT: days of therapy; DDD: defined daily dose; LC-BSI: laboratory confirmed bloodstream infection; LOT: length of therapy; NICU: neonatal intensive care unit; PDD: prescribed daily dose; PNSN: Polish Neonatal Surveillance Network; VLBW: very low birth weight; PCR: polymerase chain reaction; MALDI-TOF: matrix assisted laser desorption ionisation, MALDI, time of flight, TOF.

Authors' contributions
AR designed the study and was a major contributor in writing the manuscript. PA performed statistical analysis; MBK, EG, MN, AK, DP collected the data on the wards; MB have given final approval of the version to be published. All authors read and approved the final manuscript.

Acknowledgements
Not applicable.

Competing interests
The authors declare that they have no competing interests.

Availability of data and materials
The datasets analyzed during the presented study available from the corresponding author on reasonable request.

Ethics approval
The study was approved by the Bioethics Committee of Jagiellonian University Medical College-No. KBET/221/B/2011.

Funding
The project of the Polish Neonatology Surveillance Network was funded by the Polish Ministry of Science and Higher Education (Decision No. 669/E-215-2012). The funder had no impact on the design of the study and collection, analysis and interpretation of data and writing the manuscript.

Received: 5 March 2016 Accepted: 23 March 2017 Published online: 31 March 2017

References
1. Wójcikowska-Mach J, Borszewska-Kornacka M, Domanska J, Gadzinowski J, Gulczyńska E, Helwich E, et al. Early-onset Infections of very-low-birth-weight infants in Polish neonatal intensive care units. Pediatr Infect Dis J. 2012;31(7):691–5.
2. Ronnestad A, Abrahamsen TG, Medbo S, Reigstad H, Lossius K, Kaaresen PI, et al. Septicemia in the first week of life in a Norwegian National Cohort of extremely premature infants. Pediatrics. 2005;115:e626–8. doi:10.1542/peds.2004-1834.
3. Stoll BJ, Hansen NI, Bell EF, Shankaran S, Laptook AR, Walsh MC, et al. The Eunice Kennedy Shriver National Institute of Child Health and Human Development Neonatal Research Network: neonatal outcomes of extremely preterm infants from the NICHD Neonatal Research Network. Pediatrics. 2010;123(3):443–56. doi:10.1542/peds.2009-2959.
4. Klinger G, Levy I, Sirola L, Boyko V, Lerner-Geva L, Reichman B. Outcome of early-onset sepsis in a national cohort of very low birth weight infants. Pediatrics. 2010;125(4):e736–40. doi:10.1542/peds.2009-2017.
5. Venspirt P, Sharland M, Bielicki J, Draper N, Vankereckoven V, Goossens H. The antibiotic resistance and prescribing in European children projects. A neonatal and pediatric antimicrobial web-based point prevalence survey in 73 hospitals worldwide. Pediatr Infect Dis J. 2013;32(6):242–53.
6. Fridkin SK, Kaufman D, Edwards J, Shetty S, Horan T. Changing incidence of Candida bloodstream infections among NICU patients in the United States. 1995–2009. Pediatr. 2006;117(5):1680–7.
7. Wójcikowska-Mach J, Borszewska-Kornacka M, Domanska J, Gadzinowski J, Gulczyńska E, Nowiczewski M, et al. Late-onset bloodstream infections of very-low-birth-weight infant. Data from the Polish Neonatology Surveillance Network in 2009–2011. J BMC Infect Dis. 2014;14(1):339. doi:10.1186/1471-2334-14-339.
8. Schwab F, Geffers C, Barwolff S, Ruden H, Gastmeier P. Reducing neonatal nosocomial bloodstream infections through participation in a national surveillance system. J Hosp Infect. 2007;65:319–25.
9. Makhoul IR, Sujov P, Smolink T, Lusky A, Reichman B. Pathogen-specific early-mortality in very low birth weight infants with late-onset sepsis: a national survey. Clin Infect Dis. 2008;40:218–24.
10. Grohskopf LA, Huikins WC, Sinkowitz-Cochran RL, Levine GL, Goldmann DA, Jarvis WR. Use of antimicrobial agents in United States neonatal and pediatric intensive care patients. Pediatr Infect Dis J. 2005;24:766–73.
11. Liem Y, van den Hoogen A, Rademaker C, Egberts CT, Fleer F, Krediet TG. Antibiotic weight-adjusting: slimming down on antibiotic use in a NICU. Acta Pediatria. 2010;99:1900–2.
12. WHO Collaborating Centre for Drug Statistics Methodology. Guidelines for ATC classification and DDD assignment. 2010. Oslo, 2009. ISBN 1726-4898, ISBN 978-82-8082-369-4.
13. Porta A, Hisa Y, Doeholt K, Mensen E, Spyridis N, Bielicki J, et al. Comparing neonatal and paediatric antibiotic prescribing between hospitals: a new algorithm to help international benchmarking. J Antimicrob Chemother. 2012;67:1278–86.
14. Berrington A. Antimicrobial prescribing in hospitals: be careful what you measure. J Antimicrob Chemother. 2010;65:163–8.
15. Gerber JS, Kronman MP, Ross RK, Hersh AL, Newland JG, Metjian TA, et al. Identifying targets for antimicrobial stewardship in children’s hospitals. Infect Control Hosp Epidemiol. 2013;34(12):1252–8.
16. Haug JB, Reikvam A. WHO defined daily doses for hospital- and adjusted defined daily doses: impact on results of antibiotic use surveillance: J Antimicrob Chemother. 2013;68:2940–7.
17. Gastmeier P, Geffers C, Schwab F, Fitzer J, Oblader M, Ruden H. Development of a surveillance system for nosocomial infections: the component for neonatal intensive care in Germany. J Hosp Infect. 2004;57:126–31.
18. Brodie SB, Sands KE, Gray JE, Parker RA, Goldmann DA, Davis RB, Richard-son DK. Occurrence of nosocomial bloodstream infections in six neonatal intensive care units. Pediatr Infect Dis J. 2000;19:56–65.
19. Drews MB, Ludwig AC, Leititis JU, Daschner FD. Low birth weight and nosocomial infection of neonates in a neonatal intensive care unit. J Hosp Infect. 1995;30:65–72.
20. Krawczyk-Wyrwicka I, Piotrowski A, Rydlewska-Liszkowska I, Hanke W. Costs of intensive care of newborns born prematurely. Pzt Epidemiol. 2006;60:155–62.
21. Wójcikowska-Mach J, Adamski P, Borszewska-Kornacka M, Gulczyńska E, Nowiczewski M, et al. Infections and risk-adjusted length of stay and hospital mortality in Polish neonatology intensive care units. Int J Infect Dis. 2013;55:87–92.
22. Edwards JR, Peterson KD, Mu Y, Banwrjee S, Allen-Bridson K, Morrell G, et al. National healthcare safety network (nhsn) report: data summary for 2006 through 2008, issued december 2009. Am J Infect Control. 2009;37:783–805. doi:10.1016/j.ajic.2009.10.001.
23. Gikas A, Roumbelaki M, Bagatzouni-Pieridou D, Alexandrou M, Zinieri V, Dimitriadis I, et al. Device-associated infections in the intensive care units of Cyprus: results of the first national incidence study. Infection. 2010;38:165–71.

24. Huang YC, Wang YH, Chou YH, Lien RI. Significance of coagulase-negative staphylococci isolated from a single blood culture from neonates in intensive care. Ann Trop Paediatr. 2006;26(4):311–8.

25. Van der Zwet WC, Kaiser AM, van Elburg RM, Berkhof J, Fetter WP, Parlevliet GA, et al. Nosocomial infections in a Dutch neonatal intensive care unit: surveillance study with definitions for infection specifically adapted for neonates. J Hosp Infect. 2005;61:300–11.

26. Liem Y, Heerdink A, Egberts A, Rademaker CM. Quantifying antibiotic use in pediatrics: a proposal for neonatal DDDs. Eur J Clin Microbiol Infect Dis. 2010;29:1301–3.

27. Barlam T, Cosgrove S, Abbo L, MacDougall C, Schuetz AN, Septimus EJ, et al. Implementing an antibiotic stewardship program: guidelines by the Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America. Clin Infect Dis. 2016;62(10):e51–77.

28. Różańska A, Wójkowska-Mach J, Borszewska-Kornacka M, Ćmiel A, Gadzinowski J, Gulczyńska E, et al. Antibiotic consumption and its costs of purchase in Polish Neonatology Networks Units. Przegl Epidemiol. 2012;66:513–9.

29. Wójkowska-Mach J, Różańska A, Borszewska-Kornacka M, Domarśka J, Gadzinowski J, Gulczyńska E, et al. Antibiotic consumption and its costs of purchase in Polish Neonatology Networks Units. Przegl Epidemiol. 2012;66:513–9.

30. Garcia-Prats JA, Cooper TR, Schneider VF, Stager CE, Hansen TN. Rapid detection of microorganisms in blood cultures of newborn infants utilizing an automated blood culture system. Pediatrics. 2000;105(3):523–7.

31. Kaiser JR, Cassat JE, Lewno MJ. Should antibiotics be discontinued at 48 hours for negative late-onset sepsis evaluations in the neonatal intensive care unit? J Perinatol. 2002;22(6):445–7.

32. Lim HS, Chong YP, Noh YH, Jung JA, Kim YS. Exploration of optimal dosing regimens of vancomycin in patients infected with methicillin-resistant Staphylococcus aureus by modeling and simulation. J Clin Pharm Ther. 2014;39(2):196–203.

33. Ampe E, Delaere B, Hecq JD, Tulkens PM, Glupczynski Y. Implementation of a protocol for administration of vancomycin by continuous infusion: pharmacokinetic, pharmacodynamic and toxicological aspects. Int J Antimicrob Agents. 2013;41(5):439–46.

34. Sameer J, Oshoudi A, Prasad P, Delamona P, Larson E, Zaoutis T, et al. Antibiotic use in neonatal intensive care units and adherence with Centers for Disease Control and Prevention 12 step campaign to prevent antimicrobial resistance. Pediatr Infect Dis J. 2009;28(12):1047–51.

35. Friedman S, Richardson SE, Jacobs SE, O’Brien K. Systemic Candida infection in extremely low birth weight infants: short term morbidity and long term neurodevelopmental outcome. Pediatr Infect Dis J. 2000;19:499–504.

36. Manzoni P, Stolfi I, Pugni L, Decembrini L, Magnani C, Vetrano G, et al. A multicenter, randomized trial of prophylactic fluconazole in preterm neonates. N Engl J Med. 2007;356:2483–95.

37. Nieman AE, Savelkoul PH, Beishuizen A, Henrich B, Lamik B, Mackenzie CR, et al. A prospective multicenter evaluation of direct molecular detection of blood stream infection from a clinical perspective. BMC Infect Dis. 2016;16:314. doi:10.1186/s12879-016-1646-4.

38. Chen Y, Porter V, Mubareka S, Kotovich L, Simor AE. Rapid identification of bacteria directly from positive blood cultures by use of a serum separator tube, smudge plate preparation, and matrix-assisted laser desorption ionization-time of flight mass spectrometry. J Clin Microbiol. 2015;53(10):3349–52. doi:10.1128/JCM.01493-15.